Iterum Therapeutics (NASDAQ:ITRM) Announces Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Iterum Therapeutics (NASDAQ:ITRM) issued its quarterly earnings data on Friday. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.14, RTT News reports. During the same period in the prior year, the firm earned ($0.81) EPS.

Iterum Therapeutics Stock Down 5.3 %

NASDAQ:ITRM traded down $0.08 during trading hours on Friday, hitting $1.41. 1,417,147 shares of the company traded hands, compared to its average volume of 650,821. The firm’s 50-day simple moving average is $1.82 and its 200-day simple moving average is $1.44. Iterum Therapeutics has a one year low of $0.81 and a one year high of $3.02. The company has a market cap of $38.83 million, a PE ratio of -0.71 and a beta of 2.28.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.